- Home
- GENK vs HSCS Comparison
GENK vs HSCS Comparison
Compare GENK & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GENK | HSCS |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | United States |
| Employees | N/A | 12 |
| Industry | Restaurants | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 8.2M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | GENK | HSCS |
|---|---|---|
| Price | $1.93 | $2.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $5.67 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 49.4K | 8.1K |
| Earning Date | 05-12-2026 | 03-16-2026 |
| Dividend Yield | ★ 1.60% | N/A |
| EPS Growth | ★ 62.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $208,380,000.00 | N/A |
| Revenue This Year | $8.46 | $1,072.41 |
| Revenue Next Year | $8.17 | $2,700.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.12 | N/A |
| 52 Week Low | $1.50 | $2.01 |
| 52 Week High | $5.57 | $6.47 |
Technical Indicators
Market Signals| Indicator | GENK | HSCS |
|---|---|---|
| Relative Strength Index (RSI) | 51.38 | 45.76 |
| Support Level | $1.58 | $2.50 |
| Resistance Level | $2.21 | $2.79 |
| Average True Range (ATR) | 0.20 | 0.16 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 54.57 | 56.25 |
Price Performance
Historical ComparisonAbout GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.